Cancer Immunology, Immunotherapy

, Volume 59, Issue 6, pp 805–817

IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo

  • Tania Benatar
  • Ming Y. Cao
  • Yoon Lee
  • Jeff Lightfoot
  • Ningping Feng
  • Xiaoping Gu
  • Vivian Lee
  • Hongnan Jin
  • Ming Wang
  • Jim A. Wright
  • Aiping H. Young
Original Article

Abstract

Interleukin-17E (IL-17E) belongs to a novel family of cytokines that possess significant homology to IL-17. IL-17E has potent inflammatory effects in vitro and in vivo. Overexpression of IL-17E in mice results in a T helper-2 (Th2)-type immune response, which includes the expansion of eosinophils through the production of IL-5, and elevated gene expression of IL-4 and IL-13 in multiple tissues. In this study, we show that IL-17E has antitumor activity in vivo, a previously unrecognized function of IL-17E. Antitumor efficacy of IL-17E was examined in a variety of human tumor xenograft models, including melanoma, breast, lung, colon, and pancreatic cancers. Injection of recombinant IL-17E every other day resulted in significant antitumor activity in these tumor models. In addition, the combination of IL-17E with chemotherapy or immunotherapy agents showed an enhanced antitumor efficacy in human tumor xenograft models in mice as compared to either agent alone. Antitumor activity was demonstrated using different routes of administration, including intraperitoneal, intravenous, and subcutaneous injection. Anticancer activity was shown for both mouse and human forms of IL-17E, which have a high degree of sequence identity. Tumor-bearing mice treated with IL-17E showed a significant increase in serum levels of IL-5 and increased numbers of eosinophils in peripheral blood compared to the control group. Spleens isolated from IL-17E-treated mice showed a significant increase in eosinophils that correlated with antitumor activity of IL-17E in a dose–response manner. Finally, we demonstrate that B cells are necessary for IL-17E-mediated antitumor activity and that IL-17E was found to activate signaling pathways in B cells in vitro. Taken together, these data demonstrate that IL-17E has antitumor activity in vivo, and support further investigation of the potential clinical use of IL-17E as an anticancer agent.

Keywords

IL-17E Cancer Antitumor Eosinophils B-cells 

References

  1. 1.
    Aggarwal S, Gurney AL (2002) IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 71:1–8PubMedGoogle Scholar
  2. 2.
    Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, Kwan S, Menon S, Seymour B, Jackson C, Kung TT, Brieland JK, Zurawski SM, Chapman RW, Zurawski G, Coffman RL (2002) New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol 169:443–453PubMedGoogle Scholar
  3. 3.
    Dong C (2008) Regulation and pro-inflammatory function of interleukin-17 family cytokines. Immunol Rev 226:80–86CrossRefPubMedGoogle Scholar
  4. 4.
    Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9:556–567CrossRefPubMedGoogle Scholar
  5. 5.
    Barlow JL, McKenzie AN (2009) IL-25: a key requirement for the regulation of type-2 immunity. Biofactors 35:178–182CrossRefPubMedGoogle Scholar
  6. 6.
    Pan G, French D, Mao W, Maruoka M, Risser P, Lee J, Foster J, Aggarwal S, Nicholes K, Guillet S, Schow P, Gurney AL (2001) Forced expression of mouse IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. J Immunol 167:6559–6567PubMedGoogle Scholar
  7. 7.
    Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, Menon S, Clifford T, Hunte B, Lesley R, Muchamuel T, Hurst SD, Zurawski G, Leach MW, Gorman DM, Rennick DM (2001) IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15:985–995CrossRefPubMedGoogle Scholar
  8. 8.
    Ikeda K, Nakajima H, Suzuki K, Kagami S, Hirose K, Suto A, Saito Y, Iwamoto I (2003) Mast cells produce interleukin-25 upon Fc epsilon RI-mediated activation. Blood 101:3594–3596CrossRefPubMedGoogle Scholar
  9. 9.
    Owyang AM, Zaph C, Wilson EH, Guild KJ, McClanahan T, Miller HR, Cua DJ, Goldschmidt M, Hunter CA, Kastelein RA, Artis D (2006) Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med 203:843–849CrossRefPubMedGoogle Scholar
  10. 10.
    Feng N, Jin H, Wang M, Du C, Wright JA, Young AH (2003) Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts. Cancer Chemother Pharmacol 51:247–255PubMedGoogle Scholar
  11. 11.
    Du C, Feng N, Jin H, Wang M, Wright JA, Young AH (2003) Preclinical efficacy of Virulizin in human breast, ovarian and prostate tumor models. Anticancer Drugs 14:289–294CrossRefPubMedGoogle Scholar
  12. 12.
    Du C, Feng N, Jin H, Lee V, Wang M, Wright JA, Young AH (2003) Macrophages play a critical role in the anti-tumor activity of virulizin. Int J Oncol 23:1341–1346PubMedGoogle Scholar
  13. 13.
    Cao MY, Lee Y, Feng N, Li H, Du C, Miao D, Li J, Lee V, Jin H, Wang M, Gu X, Wright JA, Young AH (2005) NK cell activation and tumor infiltration are involved in the antitumor mechanism of Virulizin. Cancer Immunol Immunother 54:229–242CrossRefPubMedGoogle Scholar
  14. 14.
    Benatar T, Cao MY, Lee Y, Li H, Feng N, Gu X, Lee V, Jin H, Wang M, Der S, Lightfoot J, Wright JA, Young AH (2008) Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors. Cancer Immunol Immunother 57:1757–1769CrossRefPubMedGoogle Scholar
  15. 15.
    Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, Yohem KH, Gilmore LB, Seftor RE, Nakajima M, Hendrix MJ (1991) Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer 47:227–237CrossRefPubMedGoogle Scholar
  16. 16.
    Wehrend A, Hetzel U, Huchzermeyer S, Klein C, Bostedt H (2004) Sirius red is able to selectively stain eosinophil granulocytes in bovine, ovine and equine cervical tissue. Anat Histol Embryol 33:180–182CrossRefPubMedGoogle Scholar
  17. 17.
    Cao MY, Lee Y, Feng NP, Al-Qawasmeh RA, Viau S, Gu XP, Lau L, Jin H, Wang M, Vassilakos A, Wright JA, Young AH (2004) NC381, a novel anticancer agent, arrests the cell cycle in G0–G1 and inhibits lung tumor cell growth in vitro and in vivo. J Pharmacol Exp Ther 308:538–546CrossRefPubMedGoogle Scholar
  18. 18.
    Kim MR, Manoukian R, Yeh R, Silbiger SM, Danilenko DM, Scully S, Sun J, DeRose ML, Stolina M, Chang D, Van GY, Clarkin K, Nguyen HQ, Yu YB, Jing S, Senaldi G, Elliott G, Medlock ES (2002) Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood 100:2330–2340CrossRefPubMedGoogle Scholar
  19. 19.
    Roboz GJ, Rafii S (1999) Interleukin-5 and the regulation of eosinophil production. Curr Opin Hematol 6:164–168CrossRefPubMedGoogle Scholar
  20. 20.
    Tian E, Sawyer JR, Largaespada DA, Jenkins NA, Copeland NG, Shaughnessy JD Jr (2000) Evi27 encodes a novel membrane protein with homology to the IL17 receptor. Oncogene 19:2098–2109CrossRefPubMedGoogle Scholar
  21. 21.
    Tato CM, Laurence A, O’Shea JJ (2006) Helper T cell differentiation enters a new era: le roi est mort; vive le roi!. J Exp Med 203:809–812CrossRefPubMedGoogle Scholar
  22. 22.
    Fallon PG, Ballantyne SJ, Mangan NE, Barlow JL, Dasvarma A, Hewett DR, McIlgorm A, Jolin HE, McKenzie AN (2006) Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J Exp Med 203:1105–1116CrossRefPubMedGoogle Scholar
  23. 23.
    Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8:618–631CrossRefPubMedGoogle Scholar
  24. 24.
    Goswami S, Angkasekwinai P, Shan M, Greenlee KJ, Barranco WT, Polikepahad S, Seryshev A, Song LZ, Redding D, Singh B, Sur S, Woodruff P, Dong C, Corry DB, Kheradmand F (2009) Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma. Nat Immunol 10:496–503CrossRefPubMedGoogle Scholar
  25. 25.
    Lotfi R, Lee JJ, Lotze MT (2007) Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother 30:16–28CrossRefPubMedGoogle Scholar
  26. 26.
    Grimaldi JC, Yu NX, Grunig G, Seymour BW, Cottrez F, Robinson DS, Hosken N, Ferlin WG, Wu X, Soto H, O’Garra A, Howard MC, Coffman RL (1999) Depletion of eosinophils in mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3). J Leukoc Biol 65:846–853PubMedGoogle Scholar
  27. 27.
    Lee J, Ho WH, Maruoka M, Corpuz RT, Baldwin DT, Foster JS, Goddard AD, Yansura DG, Vandlen RL, Wood WI, Gurney AL (2001) IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem 276:1660–1664CrossRefPubMedGoogle Scholar
  28. 28.
    Rickel EA, Siegel LA, Yoon BR, Rottman JB, Kugler DG, Swart DA, Anders PM, Tocker JE, Comeau MR, Budelsky AL (2008) Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 181:4299–4310PubMedGoogle Scholar
  29. 29.
    Takatsu K, Kouro T, Nagai Y (2009) Interleukin 5 in the link between the innate and acquired immune response. Adv Immunol 101:191–236CrossRefPubMedGoogle Scholar
  30. 30.
    Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, Smyth MJ, Parish CR (2007) Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 178:4222–4229PubMedGoogle Scholar
  31. 31.
    Fernández-Aceñero MJ, Galindo-Gallego M, Sanz J, Aljama A (2000) Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 88:1544–1548CrossRefPubMedGoogle Scholar
  32. 32.
    Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brünner N, Moesgaard F (1999) Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 189:487–495CrossRefPubMedGoogle Scholar
  33. 33.
    Ishibashi S, Ohashi Y, Suzuki T, Miyazaki S, Moriya T, Satomi S, Sasano H (2006) Tumor-associated tissue eosinophilia in human esophageal squamous cell carcinoma. Anticancer Res 26:1419–1424PubMedGoogle Scholar
  34. 34.
    Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E (2002) Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99:2114–2121CrossRefPubMedGoogle Scholar
  35. 35.
    Kryczek I, Wei S, Szeliga W, Vatan L, Zou W (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114:357–359CrossRefPubMedGoogle Scholar
  36. 36.
    Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485–517CrossRefPubMedGoogle Scholar
  37. 37.
    Cirée A, Michel L, Camilleri-Bröet S, Jean Louis F, Oster M, Flageul B, Senet P, Fossiez F, Fridman WH, Bachelez H, Tartour E (2004) Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer 112:113–120CrossRefPubMedGoogle Scholar
  38. 38.
    Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W (2007) Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178:6730–6733PubMedGoogle Scholar
  39. 39.
    Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ (2003) Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56:171–182CrossRefPubMedGoogle Scholar
  40. 40.
    Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141–1149CrossRefPubMedGoogle Scholar
  41. 41.
    Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112:362–373CrossRefPubMedGoogle Scholar
  42. 42.
    Kleinschek MA, Owyang AM, Joyce-Shaikh B, Langrish CL, Chen Y, Gorman DM, Blumenschein WM, McClanahan T, Brombacher F, Hurst SD, Kastelein RA, Cua DJ (2007) IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med 204:161–170CrossRefPubMedGoogle Scholar
  43. 43.
    Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9:361–371CrossRefPubMedGoogle Scholar
  44. 44.
    Kundu JK, Surh YJ (2008) Inflammation: gearing the journey to cancer. Mutat Res 659:15–30CrossRefPubMedGoogle Scholar
  45. 45.
    Wong CK, Cheung PF, Ip WK, Lam CW (2005) Interleukin-25-induced chemokines and interleukin-6 release from eosinophils is mediated by p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, and nuclear factor-kappaB. Am J Respir Cell Mol Biol 33:186–194CrossRefPubMedGoogle Scholar
  46. 46.
    Maezawa Y, Nakajima H, Suzuki K, Tamachi T, Ikeda K, Inoue J, Saito Y, Iwamoto I (2006) Involvement of TNF receptor-associated factor 6 in IL-25 receptor signaling. J Immunol 176:1013–1018PubMedGoogle Scholar
  47. 47.
    Capobianco A, Manfredi AA, Monno A, Rovere-Querini P, Rugarli C (2008) Melanoma and lymphoma rejection associated with eosinophil infiltration upon intratumoral injection of dendritic and NK/LAK cells. J Immunother 31:458–465CrossRefPubMedGoogle Scholar
  48. 48.
    Immunodeficient Models Datasheet, Charles River Laboratories (http://www.criver.com/flex_content_area/documents/rm_rm_d_immunodeficient_models.pdf)
  49. 49.
    Puxeddu I, Alian A, Piliponsky AM, Ribatti D, Panet A, Levi-Schaffer F (2005) Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol 37:628–636CrossRefPubMedGoogle Scholar
  50. 50.
    Puxeddu I, Ribatti D, Crivellato E, Levi-Schaffer F (2005) Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol 116:531–536CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Tania Benatar
    • 1
    • 2
  • Ming Y. Cao
    • 1
    • 3
  • Yoon Lee
    • 1
  • Jeff Lightfoot
    • 1
  • Ningping Feng
    • 1
  • Xiaoping Gu
    • 1
  • Vivian Lee
    • 1
  • Hongnan Jin
    • 1
  • Ming Wang
    • 1
  • Jim A. Wright
    • 1
  • Aiping H. Young
    • 1
  1. 1.Research and Development DepartmentLorus Therapeutics Inc.TorontoCanada
  2. 2.Sunnybrook and Health Sciences Centre, Molecular and Cellular BiologyTorontoCanada
  3. 3.BGTD, Health CanadaOttawaCanada

Personalised recommendations